PaLM Conf Minutes 2016-Sept-14

Back to IHE Pathology and Laboratory Medicine (PaLM) Domain

Back to IHE Pathology and Laboratory Medicine (PaLM)Technical Committee Page

Recording

The recording for this meeting can be downloaded here:

Attendees

Francois Macary, Co-Chair	Phast
Raj Dash, Co-Chair	CAP
Riki Merrick, Co-Chair	APHL
Carolyn Knapik	CAP, secretariat
Mary Kennedy	CAP, secretariat
Alessandro Sulis	CRS4
Daniel Mancusi	Systelab
Dan Rutz	Epic
David de Mena	SAS
Dmytro Rud	Roche
Francesca Frexia	CRS4
Francesca Vanzo	Arsenal IT
Gunter Haroske	IHE Germany
James Harrison	CAP
JD Nolen	Cerner
Laurent Lardin	bioMerieux
Megumi Kondo	Sakura Finetek Japan

Minutes

Agenda review

• 1st hour
  • Update on cochair election – Mary:

• Have received the required number of voters, so voting is now closed.
• Riki Merrick and Francois have both been re-elected unanimously.
• Current status of SET – Alessandro:
• Added the specimen event list.
• “Specimen aliquoted” - what is the difference to the “Specimen derived” (besides being biobank)?
• An aliquoted specimen is a type of derived specimen.
• Aliquoted = body fluid specimen.
• Derived includes creation of subparts in AP lab.
• Can someone send a use case for AP lab derived specimen and other pathology domain specific use cases?
• Categories are unchanged from F2F version.
• Simplified use case diagrams.
• Do we want to alter to make clearer that the SEI and SET may sit in different locations?
• Need one for each organization  (create them as box outlines) of SEI and SET.
• May also apply to multi-facility set up in the same organization. For same organization, just one SEI and SET, but include a statement that this is an example of software architecture, among others.
• So far we have the same set up – collection location -> receiving location -> testing location.
• Should we use the same words for all the use cases and a single diagram where applicable?
• Different processes for inter-organization over longer distance and intra-organization (requirements of more robust shipping manifest, packaging, etc.) compared to the same building.
• Biobanking use case described – is it generic enough?
• Probably should explicitly document  the retrieval for shipment out of biobank (covered in other use cases, so should reference that).
• Improvement of systems in the future: Full chain of custody and audit change when more than the queried specimen are pulled from the biobank temporarily, since the specimen is in the same holder.
• This could be handled if the specimen location is part of these transactions, then the systems can do queries on all specimen in the same holder location(s).
• Fully mapping inventory of specimen (similar to inventory management) on both sides (biobank and consumer) of the testing results (they don’t need the locations, but the related changes that happened because of the locations).
• Arranging metadata needed for each of the use cases – in Vol 2, specifically for the biobank use case.
• Agenda Review for November 9 – 11 F2F Meeting in Chicago: please review here and send suggestions via google group:  "http://wiki.ihe.net/index.php/PaLM_F2F_Agenda_2016-Nov"
• APSR 2.0
• Still making progress on the document – Vol 1 completed, still discussion on Vol 3 and 4 changes.
• Keeping the OID usage updated as well.
• Wiki link: "http://wiki.hl7.de/index.php?title=IG:Pathologiebefund"